Kinnate Biopharma Inc. (KNTE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

11975 EL CAMINO REAL, STE 101 SAN DIEGO, CA 92130

Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.

Data as of 2021-10-09 10:53:16 -0400
Market Cap914.576 Million Shares Outstanding43.676 Million Avg 30-day Volume190.538 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-13.02 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low48.75 / 17.58 Next Earnings Date2021-11-15 Price to Cash FLow (P/CF) -49.0161
Data provided by IEX Cloud
View SEC Filings from KNTE instead.

View recent insider trading info

Funds Holding KNTE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KNTE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SABZEVARI HELEN

  • Director
40,501 2021-06-24 2

MITCHELL DEAN J

  • Director
20,250 2021-06-11 2

FLAHERTY KEITH T.

  • Director
20,250 2021-06-11 2

SMALDONE ALSUP LAURIE

  • Director
20,250 2021-06-11 2

EPPERLY MELISSA B,

  • Director
20,250 2021-06-11 2

KRISHNAMOHAN NEHA CHIEF FINANCIAL OFFICER

  • Officer
0 2021-06-07 2

MELTZ MARK A COO GENERAL COUNSEL TREASURER

  • Officer
0 2021-02-12 2

FARZAN NIMA CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2021-02-12 2

WILLIAMS RICHARD THOMAS CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-12 2

MURPHY ERIC ANTHONY CHIEF SCIENTIFIC OFFICER

  • Officer
0 2021-02-12 2

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VII LLC

ORBIMED GENESIS GP LLC

ORBIMED CAPITAL LLC

3,847,929 2020-12-07 3

GORDON CARL L

3,847,929 2020-12-07 4

TANANBAUM JAMES B.

10,838,311 2020-12-07 4

FORESITE CAPITAL MANAGEMENT IV, LLC

FORESITE CAPITAL FUND IV, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

  • 10% Owner
10,838,311 2020-12-07 2

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VII LLC

ORBIMED CAPITAL LLC

750,000 2020-12-02 3

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VII LLC

ORBIMED GENESIS GP LLC

0 2020-12-02 3

KALDOR STEPHEN W

1,615,826 2020-12-02 1

ROME MICHAEL E

0 2020-12-02 2

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
KINNATE BIOPHARMA INC KNTE 2021-10-15 22:15:04 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 21:45:03 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 21:15:03 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 20:45:03 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 20:15:03 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 19:45:03 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 19:15:04 UTC -0.3508 0.4208 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 18:45:03 UTC -0.3522 0.4222 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 18:15:03 UTC -0.3522 0.4222 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 17:45:03 UTC -0.3522 0.4222 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 17:15:03 UTC -0.3522 0.4222 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 16:45:03 UTC -0.3633 0.4333 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 16:15:03 UTC -0.3633 0.4333 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 15:45:03 UTC -0.3633 0.4333 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 15:15:03 UTC -0.3633 0.4333 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 14:45:02 UTC -0.3841 0.4541 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 14:15:03 UTC -0.3841 0.4541 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 13:45:03 UTC -0.3841 0.4541 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 13:15:03 UTC -0.3841 0.4541 150000
KINNATE BIOPHARMA INC KNTE 2021-10-15 12:45:03 UTC -0.3841 0.4541 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments